acute myeloid leukemia (AML) | Aplastic Anemia & MDS International Foundation

acute myeloid leukemia (AML)

2021 March for Marrow California - Virtual Walk and 5K

Help us continue to support the patients served by AAMDSIF by registering to run in our 2021 Virtual Walk and 5K or simply by donating. We look forward to walking and running with you the week of April 24 - May 1, 2021, and continuing the celebration of the brave patients and families that are fighting

Event Date: 
Sat, 04/24/2021 to Sat, 05/01/2021
Community Event Type: 

2021 March for Marrow Texas - VIRTUAL Walk and 5K

Join together virtually with fellow patients, families, caregivers, and friends to raise awareness for

Event Date: 
Sat, 03/27/2021 to Sat, 04/03/2021
Community Event Type: 

David Jacobsohn, MD, ScM

Jacobsohn, David
Division Chief, Blood and Marrow Transplanation
Children's National

David Jacobsohn, MD, ScM is the Division Chief, Blood and Marrow Transplanation at Children's National Hospital in Washington, D.C.   Previously, he was at Children’s Memorial Hospital in Chicago, where he served as a member of the Stem Cell Transplant Program staff and as the Director of the Chronic Graft-versus-Host Disease Clinic. He has lectured widely on GvHD/BMT in Europe, Latin America, and the United States. Dr.

Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp

Author(s): 
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M
Primary Author: 
Bejanyan N
Journal Title: 
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation
Original Publication Date: 
Sep 2020

Myeloablative (MAC) as compared to reduced-intensity conditioning (RIC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience

Author(s): 
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM
Primary Author: 
Bewersdorf JP
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Sep 2020

Mutations in the tumor suppressor gene TP53 are detected in 5-10% of patients with